Allogene Therapeutics (ALLO)
(Real Time Quote from BATS)
$2.86 USD
+0.01 (0.18%)
Updated Apr 26, 2024 12:18 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Company Summary
South San Francisco, CA-based Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company primarily focused on developing and commercializing genetically engineered allogeneic T cell therapies for cancer treatment.
The company has multiple pipeline candidates in the clinical stage of development, including CAR T cell product candidates — ALLO-501, cemacabtagene ansegedleucel (cema-cel, or formerly ALLO-501A), ALLO-605, ALLO-316 and ALLO-715 — and a monoclonal antibody (mAB), ALLO-647.
In January 2024, Allogene announced that it is deprioritizing two pivotal mid-stage studies, namely ALPHA2 and EXPAND, evaluating cema-cel in third-line large B cell lymphoma (LBCL). ...
Company Summary
South San Francisco, CA-based Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company primarily focused on developing and commercializing genetically engineered allogeneic T cell therapies for cancer treatment.
The company has multiple pipeline candidates in the clinical stage of development, including CAR T cell product candidates — ALLO-501, cemacabtagene ansegedleucel (cema-cel, or formerly ALLO-501A), ALLO-605, ALLO-316 and ALLO-715 — and a monoclonal antibody (mAB), ALLO-647.
In January 2024, Allogene announced that it is deprioritizing two pivotal mid-stage studies, namely ALPHA2 and EXPAND, evaluating cema-cel in third-line large B cell lymphoma (LBCL). Management intends to focus on developing cema-cel as a frontline treatment for LBCL patients. In this regard, Allogene has initiated start-up activities for the phase II ALPHA3 study to evaluate cema-cel in first-line LBCL patients.
ALLO-715 and ALLO-605 are being evaluated in the phase I UNIVERSAL study and phase I IGNITE study, respectively, for the same indication — r/r multiple myeloma (MM). ALLO-605 is also the company’s first anti-BCMA TurboCAR T cell therapy. ALLO-316 is being evaluated in a phase I TRAVERSE study for advanced or metastatic clear cell renal cell carcinoma (ccRCC). The mAB candidate, ALLO-647, is part of the lymphodepletion regimen, which is likely to increase the potency of allogeneic CAR T cell therapies.
The company has licensing agreements with companies, including Pfizer, for gaining rights to several technologies or candidates. The company also has a joint venture with Overland Pharma.
With no marketed products in its portfolio, Allogene only generates collaboration revenues. The company generated $0.1 million in 2023, down 39% year over year.
General Information
Allogene Therapeutics, Inc
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-457-2700
Fax: NA
Email: ir@allogene.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 5/1/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.39 |
Current Year EPS Consensus Estimate | -1.69 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 5/1/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 2.86 |
52 Week High | 6.89 |
52 Week Low | 2.23 |
Beta | 0.81 |
20 Day Moving Average | 1,682,317.38 |
Target Price Consensus | 13.80 |
4 Week | -36.13 |
12 Week | -23.05 |
YTD | -11.06 |
4 Week | -33.52 |
12 Week | -25.21 |
YTD | -15.97 |
Shares Outstanding (millions) | 170.72 |
Market Capitalization (millions) | 487.41 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 34.85% |
vs. Previous Quarter | -16.22% |
vs. Previous Year | -55.32% |
vs. Previous Quarter | -51.16% |
Price/Book | 0.94 |
Price/Cash Flow | NA |
Price / Sales | 3,046.34 |
3/31/24 | NA |
12/31/23 | -53.76 |
9/30/23 | -54.01 |
3/31/24 | NA |
12/31/23 | -43.24 |
9/30/23 | -43.63 |
3/31/24 | NA |
12/31/23 | 12.38 |
9/30/23 | 12.58 |
3/31/24 | NA |
12/31/23 | 12.38 |
9/30/23 | 12.58 |
3/31/24 | NA |
12/31/23 | -194,088.09 |
9/30/23 | -178,954.28 |
3/31/24 | NA |
12/31/23 | -202,366.25 |
9/30/23 | -178,954.28 |
3/31/24 | NA |
12/31/23 | -344,489.50 |
9/30/23 | -183,138.14 |
3/31/24 | NA |
12/31/23 | 3.04 |
9/30/23 | 3.48 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | NA |
3/31/24 | NA |
12/31/23 | 0.00 |
9/30/23 | 0.00 |
3/31/24 | NA |
12/31/23 | 0.00 |
9/30/23 | 0.00 |